Global POC Coagulation Analyzers/Monitors Market Size, Trends & Analysis - Forecasts to 2026

The point of care coagulation monitors or analyzers market is estimated to witness a significant growth of CAGR 7.2% during the forecast period (2020-2026). Point-of-care coagulation devices monitor or measure the Prothrombin time/international normalized ratio (PT/INR) on fingerstick capillary blood. Such data is the used to prescribe the patients who suffer Haemophilia, for oral anticoagulant therapy with vitamin K antagonists. A major factor contributing to the growth of this market is the high prevalence of coagulation disorders such as Haemophilia, and Von Willebrand disease. As per a CDC report of 2018, Haemophilia A affects 1 in 5,000 US citizen every year and ~400 babies are born with Haemophilia A disorder every year. This disease is so common that the exact number of patients has still not been registered in the States. Moreover, the out of the diagnosed patients, 75% of them do not even receive treatment or have access to insufficient medical guidance. Hence, the importance of diagnosis and treatment has given rise to adoption of point of care analyzers.

Furthermore, rising aging population clubbed with rising need for home based minimally invasive testing will help propel the growth of this market. For instance, as per the reports by who, from, 2015 to 2050, the proportion of the world's population over 60 years will approximately double from 12% to 22%. And by 2050, 80% of older people will be living in low- and middle-income countries too.

Request for a sample copy of the report at: https://www.globalmarketestimates.com/market-report/global-poc-coagulation-analyzers-monitors-market-2193

These analyzers or monitors play an important during perioperative procedures in hospital settings and hence will drive the market immensely. Moreover, increasing prevalence of the rapid adoption of POC testing devices for home based testing, rising consumption of anticoagulant drugs (for the treatment of thrombosis and associated disorders, including stroke, myocardial infarction and pulmonary embolism), and rising demand for coagulation monitoring in preoperative and postoperative screening are few of the factors driving the market. Faster turn-around time, cost effectiveness of the portable kits and lack of loss of blood in traditional coagulation testing technique will add fuel to the growth of the market. Such analyzers are convenient to use by both patient and hospital staff, lightweight to carry, and handheld based design for daily use. Also, these analyzers do not need an invasive venous blood draw, which can reduce patient’s visit to an OPD or hospital set up from 3-4 hours to as less as 20 minutes.

This market is segmented into by component (analyzers/monitoring devices, reagents, consumables & accessories and service), by portability (benchtop and handheld), by operation (semi-automatic and automatic), by methodology (ACT, Whole blood PT/INR, Whole blood aPTT, viscoelastic coagulation monitoring), by end user (hospitals, diagnostic labs, outpatient anticoagulation clinics, home care settings).

In addition, with the increasing demand for POC monitoring, the major medical device players are also keen on launching and offering POC coagulation devices. Some of which are F. Hoffmann-La Roche AG, Abbott Laboratories, Siemens, Philips, Medtronic, Heamonetics, Hemosonics, Micropoint Bioscience, Werfen, Sienco and Cairo Medical among others. (Other companies include Instrumentation Laboratories, Kofa, Accriva, Diagon, Micropoint, Iline, MedCaptain, Bio AMD, Sclavo, Diagnostics, A& T Corporation, TECO Medical Instruments, Dialab and Acon). These companies have adopted sales strategies of research collaboration, product launch, and partnership etc. For example, in December 2019, Enzyre (Netherlands), entered into a research partnership-agreement with Takeda Pharmaceutical Company Limited (Japan) in order to develop a POC diagnostic device that will help haemophilia patients to know their coagulation status at their own homes. Also, in April 2018, Roche, announced the launch of CoaguChek Vantus system, a self-testing device, enabled with the wireless reporting of INR test results.

Although laboratory based coagulation tests are the gold standard of reference in instances of an unexpected patient, but POC based testing offers significant advantages for both the hospital and the patient.

Browse the report at: https://www.globalmarketestimates.com/market-report/global-poc-coagulation-analyzers-monitors-market-2193